FPF
AUPH icon

FNY Partners Fund’s Aurinia Pharmaceuticals AUPH Stock Holding History

FNY Partners Fund’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3,000
Closed -$18K – 434
2017
Q3 		$18K Hold
3,000
– – ﹤0.01% 382
2017
Q2 		$18K Buy
3,000
+2,500
+500% +$16.8K ﹤0.01% 350
2017
Q1 		$3K Buy
+500
New +$2.31K ﹤0.01% 1237

Other funds holding AUPH

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FNY Partners Fund's AUPH Position: Q4 2017 in Review

FNY Partners Fund sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2017, closing a stake of 3,000 shares — an estimated $18K sold.

FNY Partners Fund first reported a position in AUPH in Q1 2017 and held it in 3 quarters. The position peaked at $18K in Q3 2017. 69 funds tracked by Wall St. Rank hold AUPH as of Q4 2017.

  • FNY Partners Fund reported no remaining Aurinia Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • FNY Partners Fund sold 3,000 Aurinia Pharmaceuticals shares in Q4 2017, an estimated $18K.
  • FNY Partners Fund first reported a position in Aurinia Pharmaceuticals in Q1 2017 and held it in 3 quarters.
  • FNY Partners Fund's Aurinia Pharmaceuticals position peaked at $18K in Q3 2017.
  • 69 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2017.

Based on FNY Partners Fund's 13F filing for Q4 2017, filed 24 Jan 2018.